JP2010515729A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010515729A5 JP2010515729A5 JP2009545545A JP2009545545A JP2010515729A5 JP 2010515729 A5 JP2010515729 A5 JP 2010515729A5 JP 2009545545 A JP2009545545 A JP 2009545545A JP 2009545545 A JP2009545545 A JP 2009545545A JP 2010515729 A5 JP2010515729 A5 JP 2010515729A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- alkyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 claims description 36
- 150000003839 salts Chemical class 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 230000000954 anitussive effect Effects 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 229940124584 antitussives Drugs 0.000 claims description 2
- 229940124630 bronchodilator Drugs 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 5
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 5
- 125000003386 piperidinyl group Chemical group 0.000 claims 5
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000003434 antitussive agent Substances 0.000 claims 1
- 239000000168 bronchodilator agent Substances 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 description 19
- 108091005804 Peptidases Proteins 0.000 description 19
- 239000004365 Protease Substances 0.000 description 19
- 108010031970 prostasin Proteins 0.000 description 19
- 108091006146 Channels Proteins 0.000 description 18
- 102100029500 Prostasin Human genes 0.000 description 18
- 230000003213 activating effect Effects 0.000 description 15
- 101000798702 Homo sapiens Transmembrane protease serine 4 Proteins 0.000 description 13
- 102100032471 Transmembrane protease serine 4 Human genes 0.000 description 13
- 102100037942 Suppressor of tumorigenicity 14 protein Human genes 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 101000661807 Homo sapiens Suppressor of tumorigenicity 14 protein Proteins 0.000 description 6
- 102100022046 Brain-specific serine protease 4 Human genes 0.000 description 5
- 108010059081 Cathepsin A Proteins 0.000 description 5
- 102000005572 Cathepsin A Human genes 0.000 description 5
- 101000897856 Homo sapiens Adenylyl cyclase-associated protein 2 Proteins 0.000 description 5
- 101000896891 Homo sapiens Brain-specific serine protease 4 Proteins 0.000 description 5
- 101000836079 Homo sapiens Serpin B8 Proteins 0.000 description 5
- 101000836075 Homo sapiens Serpin B9 Proteins 0.000 description 5
- 101000798707 Homo sapiens Transmembrane protease serine 13 Proteins 0.000 description 5
- 108010028275 Leukocyte Elastase Proteins 0.000 description 5
- 108010091175 Matriptase Proteins 0.000 description 5
- 102100033174 Neutrophil elastase Human genes 0.000 description 5
- 102100032467 Transmembrane protease serine 13 Human genes 0.000 description 5
- 102000004142 Trypsin Human genes 0.000 description 5
- 108090000631 Trypsin Proteins 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000012588 trypsin Substances 0.000 description 5
- 101000598054 Homo sapiens Transmembrane protease serine 11B Proteins 0.000 description 4
- 101000637855 Homo sapiens Transmembrane protease serine 11E Proteins 0.000 description 4
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 description 4
- 101000798700 Homo sapiens Transmembrane protease serine 3 Proteins 0.000 description 4
- 101100069392 Mus musculus Gzma gene Proteins 0.000 description 4
- 102100037023 Transmembrane protease serine 11B Human genes 0.000 description 4
- 102100032001 Transmembrane protease serine 11E Human genes 0.000 description 4
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 108010036927 trypsin-like serine protease Proteins 0.000 description 3
- 102000003837 Epithelial Sodium Channels Human genes 0.000 description 2
- 108090000140 Epithelial Sodium Channels Proteins 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 2
- -1 bronchodilator Substances 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000037427 ion transport Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 0 CS(N[C@@](CCC1CCNCC1)C(N(CC(*Cc(cc1)ccc1Cl)C1)[C@@]1C(NCc1c(CN)ccc(*)c1)=O)=O)(=C)=O Chemical compound CS(N[C@@](CCC1CCNCC1)C(N(CC(*Cc(cc1)ccc1Cl)C1)[C@@]1C(NCc1c(CN)ccc(*)c1)=O)=O)(=C)=O 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 229940123991 Prostasin inhibitor Drugs 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 238000003185 biochemical assay format Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000004955 epithelial membrane Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000000420 mucociliary effect Effects 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88433407P | 2007-01-10 | 2007-01-10 | |
| US89147407P | 2007-02-23 | 2007-02-23 | |
| PCT/US2007/085366 WO2008085608A1 (en) | 2007-01-10 | 2007-11-21 | Compounds and compositions as channel activating protease inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010515729A JP2010515729A (ja) | 2010-05-13 |
| JP2010515729A5 true JP2010515729A5 (enFirst) | 2012-08-30 |
Family
ID=39148650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009545545A Ceased JP2010515729A (ja) | 2007-01-10 | 2007-11-21 | チャネル活性化プロテアーゼ阻害剤としての化合物および組成物 |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US20080176901A1 (enFirst) |
| EP (2) | EP2279777A2 (enFirst) |
| JP (1) | JP2010515729A (enFirst) |
| KR (1) | KR101084787B1 (enFirst) |
| AR (1) | AR064841A1 (enFirst) |
| AT (1) | ATE493174T1 (enFirst) |
| AU (1) | AU2007342223B2 (enFirst) |
| BR (1) | BRPI0720799A2 (enFirst) |
| CA (1) | CA2673803A1 (enFirst) |
| CL (1) | CL2008000060A1 (enFirst) |
| CO (1) | CO6190626A2 (enFirst) |
| CU (1) | CU23762B7 (enFirst) |
| CY (1) | CY1111340T1 (enFirst) |
| DE (1) | DE602007011670D1 (enFirst) |
| DK (1) | DK2104535T3 (enFirst) |
| EA (1) | EA016199B1 (enFirst) |
| EC (1) | ECSP099517A (enFirst) |
| GT (1) | GT200900196A (enFirst) |
| HN (1) | HN2009001282A (enFirst) |
| HR (1) | HRP20110201T1 (enFirst) |
| MA (1) | MA31037B1 (enFirst) |
| MX (1) | MX2009007476A (enFirst) |
| NO (1) | NO20092817L (enFirst) |
| NZ (1) | NZ577939A (enFirst) |
| PE (1) | PE20081566A1 (enFirst) |
| PL (1) | PL2104535T3 (enFirst) |
| PT (1) | PT2104535E (enFirst) |
| RS (1) | RS51644B (enFirst) |
| SV (1) | SV2009003330A (enFirst) |
| TN (1) | TN2009000294A1 (enFirst) |
| TW (1) | TW200845981A (enFirst) |
| WO (1) | WO2008085608A1 (enFirst) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2027143A2 (en) * | 2006-05-23 | 2009-02-25 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
| JP5208963B2 (ja) | 2007-01-10 | 2013-06-12 | エフ．ホフマン−ラ ロシュ アーゲー | キマーゼ阻害剤としてのスルホンアミド誘導体 |
| CA2677487A1 (en) * | 2007-02-09 | 2008-08-14 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
| SG175711A1 (en) | 2009-05-18 | 2011-12-29 | Orion Corp | Protease inhibitors |
| US10399940B2 (en) * | 2016-10-07 | 2019-09-03 | Abbvie S.Á.R.L. | Substituted pyrrolidines and methods of use |
| GB201805174D0 (en) | 2018-03-29 | 2018-05-16 | Univ Leeds Innovations Ltd | Compounds |
| WO2019231935A1 (en) | 2018-05-29 | 2019-12-05 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| MX2021011507A (es) | 2019-03-22 | 2021-12-15 | Achillion Pharmaceuticals Inc | Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento. |
| AU2020349353A1 (en) | 2019-09-17 | 2022-04-14 | Duke University | Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease |
| AU2020395306B2 (en) * | 2019-12-04 | 2025-04-24 | Omeros Corporation | MASP-2 inhibitors and methods of use |
| JP7699389B2 (ja) | 2019-12-04 | 2025-06-27 | オメロス コーポレーション | Ｍａｓｐ－２阻害剤および使用方法 |
| BR112022010895A2 (pt) | 2019-12-04 | 2022-09-06 | Omeros Corp | Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado à serina protease-2 associada à lectina de ligação ao manan |
| CN115052862A (zh) | 2019-12-04 | 2022-09-13 | 奥默罗斯公司 | Masp-2抑制剂和使用方法 |
| HUE064089T2 (hu) | 2020-04-16 | 2024-02-28 | Mereo Biopharma 4 Ltd | Alvelesztat neutrofil elasztáz inhibitort alkalmazó módszerek alfa-1-antitripszin hiány által közvetített légzõszervi megbetegedés kezelésére |
| AU2022373971A1 (en) | 2021-10-20 | 2024-04-04 | Mereo Biopharma 4 Limited | Neutrophil elastase inhibitors for use in the treatment of fibrosis |
| WO2023183405A2 (en) * | 2022-03-22 | 2023-09-28 | Alexion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement mediated disorders |
Family Cites Families (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1219606A (en) | 1968-07-15 | 1971-01-20 | Rech S Et D Applic Scient Soge | Quinuclidinol derivatives and preparation thereof |
| JPS6235216A (ja) | 1985-08-09 | 1987-02-16 | Noritoshi Nakabachi | 不均質物質層の層厚非破壊測定方法および装置 |
| GB8923590D0 (en) | 1989-10-19 | 1989-12-06 | Pfizer Ltd | Antimuscarinic bronchodilators |
| PT100441A (pt) | 1991-05-02 | 1993-09-30 | Smithkline Beecham Corp | Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso |
| WO1993018007A1 (fr) | 1992-03-13 | 1993-09-16 | Tokyo Tanabe Company Limited | Nouveau derive de carbostyrile |
| JP3192424B2 (ja) | 1992-04-02 | 2001-07-30 | スミスクライン・ビーチャム・コーポレイション | アレルギーまたは炎症疾患の治療用化合物 |
| FI944549L (fi) | 1992-04-02 | 1994-11-30 | Smithkline Beecham Corp | Allergisten ja tulehdussairauksien hoidossa käyttökelpoiset yhdisteet |
| WO1993019751A1 (en) | 1992-04-02 | 1993-10-14 | Smithkline Beecham Corporation | Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor |
| US5705487A (en) * | 1994-03-04 | 1998-01-06 | Eli Lilly And Company | Antithrombotic agents |
| US5707966A (en) * | 1994-03-04 | 1998-01-13 | Eli Lilly And Company | Antithrombotic agents |
| US5726159A (en) * | 1994-03-04 | 1998-03-10 | Eli Lilly And Company | Antithrombotic agents |
| ZA951617B (en) * | 1994-03-04 | 1997-02-27 | Lilly Co Eli | Antithrombotic agents. |
| US5914319A (en) * | 1995-02-27 | 1999-06-22 | Eli Lilly And Company | Antithrombotic agents |
| GB2299455B (en) * | 1995-03-31 | 1999-12-22 | Motorola Inc | Self phased antenna element with dielectric and associated method |
| JP2000514788A (ja) * | 1996-06-25 | 2000-11-07 | イーライ・リリー・アンド・カンパニー | 抗凝固剤 |
| GB9622386D0 (en) | 1996-10-28 | 1997-01-08 | Sandoz Ltd | Organic compounds |
| US6166037A (en) | 1997-08-28 | 2000-12-26 | Merck & Co., Inc. | Pyrrolidine and piperidine modulators of chemokine receptor activity |
| WO1999016766A1 (en) | 1997-10-01 | 1999-04-08 | Kyowa Hakko Kogyo Co., Ltd. | Benzodioxole derivatives |
| US6362371B1 (en) | 1998-06-08 | 2002-03-26 | Advanced Medicine, Inc. | β2- adrenergic receptor agonists |
| KR100563395B1 (ko) | 1998-06-30 | 2006-03-23 | 다우 글로벌 테크놀로지스 인크. | 중합체 폴리올 및 이의 제조방법 |
| GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| PL203117B1 (pl) | 1999-05-04 | 2009-08-31 | Schering Corp | Piperydynopiperydynowa pochodna użyteczna jako antagonista CCR5, zawierająca ją kompozycja farmaceutyczna i jej zastosowanie |
| SK286641B6 (sk) | 1999-05-04 | 2009-03-05 | Schering Corporation | Piperazínové deriváty užitočné ako CCR5 antagonisty, farmaceutické prípravky s ich obsahom a ich použitie |
| US6683115B2 (en) | 1999-06-02 | 2004-01-27 | Theravance, Inc. | β2-adrenergic receptor agonists |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| PL200923B1 (pl) | 1999-08-21 | 2009-02-27 | Nycomed Gmbh | Lek zawierający inhibitor PDE w połączeniu z agonistą receptoraß₂ -adrenergicznego oraz zastosowanie połączenia roflumilastu i salmeterolu |
| OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
| HUP0300832A2 (hu) | 2000-04-27 | 2003-08-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Új, lassú hatású bétamimetikumok, eljárás előállításukra és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények |
| AU2001266100B9 (en) | 2000-06-27 | 2005-10-06 | Laboratorios S.A.L.V.A.T., S.A. | Carbamates derived from arylalkylamines |
| GB0015876D0 (en) | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
| DE10038639A1 (de) | 2000-07-28 | 2002-02-21 | Schering Ag | Nichtsteroidale Entzündungshemmer |
| CA2417826A1 (en) | 2000-08-05 | 2002-02-14 | Glaxo Group Limited | 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents |
| GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| EP1345937B1 (en) | 2000-12-22 | 2005-09-28 | Almirall Prodesfarma AG | Quinuclidine carbamate derivatives and their use as m3 antagonists |
| SI1353919T1 (sl) | 2000-12-28 | 2006-12-31 | Almirall Prodesfarma Ag | Novi derivati kinuklidina in medicinske zmesi, kijih vsebujejo. |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| JP2004526720A (ja) | 2001-03-08 | 2004-09-02 | グラクソ グループ リミテッド | βアドレナリン受容体のアゴニスト |
| ATE381537T1 (de) | 2001-03-22 | 2008-01-15 | Glaxo Group Ltd | Formanilid-derivative als beta2-adrenorezeptor- agonisten |
| AR033290A1 (es) | 2001-04-30 | 2003-12-10 | Glaxo Group Ltd | Derivados antiinflamatorios de androstano |
| EP1395604B1 (en) | 2001-06-12 | 2008-06-25 | Glaxo Group Limited | Novel anti inflammatory 17.alpha.-heterocyclic-esters of 17.beta.-carbothioate androstane derivatives |
| EP2039762A3 (en) | 2001-06-21 | 2009-07-29 | Verenium Corporation | Nitralases |
| WO2003013571A1 (en) * | 2001-08-10 | 2003-02-20 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
| ES2438985T3 (es) | 2001-09-14 | 2014-01-21 | Glaxo Group Limited | Formulación de inhalación que comprende derivados de fenetanolamina para el tratamiento de enfermedades respiratorias |
| RU2004110717A (ru) | 2001-10-17 | 2005-10-20 | Юсиби, С.А. (Be) | Производные хинуклидина, способы их получения и их применение в качестве и нгибиторов м2- и/или м3- мускариновых рецепторов |
| GB0125259D0 (en) | 2001-10-20 | 2001-12-12 | Glaxo Group Ltd | Novel compounds |
| AR037517A1 (es) | 2001-11-05 | 2004-11-17 | Novartis Ag | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria |
| US6653323B2 (en) | 2001-11-13 | 2003-11-25 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
| TWI249515B (en) | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
| AU2002356759A1 (en) | 2001-12-01 | 2003-06-17 | Glaxo Group Limited | 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents |
| CA2470956C (en) | 2001-12-20 | 2011-08-02 | Laboratorios S.A.L.V.A.T., S.A. | 1-alkyl-1-azoniabicyclo[2.2.2]octane carbamate derivatives and their use as muscarinic receptor antagonists |
| AU2003202044A1 (en) | 2002-01-15 | 2003-09-09 | Glaxo Group Limited | 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents |
| AU2003201693A1 (en) | 2002-01-21 | 2003-09-02 | Glaxo Group Limited | Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents |
| GB0202216D0 (en) | 2002-01-31 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
| GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
| JP4324480B2 (ja) | 2002-03-26 | 2009-09-02 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | グルココルチコイドミメティクス、その製法、医薬組成物、及び使用 |
| EP1490317A1 (en) | 2002-03-26 | 2004-12-29 | Boehringer Ingelheim Pharmaceuticals Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| WO2003086294A2 (en) | 2002-04-11 | 2003-10-23 | Merck & Co., Inc. | 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators |
| ES2206021B1 (es) | 2002-04-16 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de pirrolidinio. |
| ATE381535T1 (de) | 2002-04-25 | 2008-01-15 | Glaxo Group Ltd | Phenethanolaminderivate |
| EP1507754A1 (en) | 2002-05-28 | 2005-02-23 | Theravance, Inc. | Alkoxy aryl beta-2 adrenergic receptor agonists |
| US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| ES2201907B1 (es) | 2002-05-29 | 2005-06-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de indolilpiperidina como potentes agentes antihistaminicos y antialergicos. |
| DE10224888A1 (de) | 2002-06-05 | 2003-12-24 | Merck Patent Gmbh | Pyridazinderivate |
| US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| DE10225574A1 (de) | 2002-06-10 | 2003-12-18 | Merck Patent Gmbh | Aryloxime |
| DE10227269A1 (de) | 2002-06-19 | 2004-01-08 | Merck Patent Gmbh | Thiazolderivate |
| WO2004000814A1 (en) | 2002-06-25 | 2003-12-31 | Merck Frosst Canada & Co. | 8-(biaryl) quinoline pde4 inhibitors |
| ES2204295B1 (es) | 2002-07-02 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de quinuclidina-amida. |
| US20060004056A1 (en) | 2002-07-02 | 2006-01-05 | Bernard Cote | Di-aryl-substituted-ethan pyridone pde4 inhibitors |
| WO2004005229A1 (en) | 2002-07-08 | 2004-01-15 | Pfizer Products Inc. | Modulators of the glucocorticoid receptor |
| GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| AR040962A1 (es) | 2002-08-09 | 2005-04-27 | Novartis Ag | Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto |
| HRP20050198A2 (hr) | 2002-08-10 | 2006-04-30 | Altana Pharma Ag | Piperidin-piridazoni i ftalazoni kao inhibitori pde4 |
| WO2004018449A1 (en) | 2002-08-10 | 2004-03-04 | Altana Pharma Ag | Piperidine-derivatives as pde4 inhibitors |
| US20060166995A1 (en) | 2002-08-10 | 2006-07-27 | Altana Pharma Ag | Piperidine-n-oxide-derivatives |
| US20060167001A1 (en) | 2002-08-10 | 2006-07-27 | Sterk Jan G | Pyridazinone-derivatives as pde4 inhibitors |
| CA2495597A1 (en) | 2002-08-17 | 2004-03-04 | Altana Pharma Ag | Novel phenanthridines |
| AU2003263216A1 (en) | 2002-08-17 | 2004-03-11 | Nycomed Gmbh | Benzonaphthyridines with PDE 3/4 inhibiting activity |
| CA2496175A1 (en) | 2002-08-21 | 2004-03-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| SE0202483D0 (sv) | 2002-08-21 | 2002-08-21 | Astrazeneca Ab | Chemical compounds |
| EP1534675B1 (en) | 2002-08-23 | 2009-02-25 | Ranbaxy Laboratories, Ltd. | Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo¬3.1.0 hexane derivatives as muscarinic receptor antagonists |
| NZ538932A (en) | 2002-08-29 | 2007-04-27 | Boehringer Ingelheim Pharma | 3-(sulfonamidoethyl)-indole derivatives for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative disease |
| CA2496459C (en) | 2002-08-29 | 2013-06-25 | Altana Pharma Ag | 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors |
| AU2003255493B8 (en) | 2002-08-29 | 2009-03-26 | Takeda Gmbh | 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors |
| GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
| JP2006096662A (ja) | 2002-09-18 | 2006-04-13 | Sumitomo Pharmaceut Co Ltd | 新規６−置換ウラシル誘導体及びアレルギー性疾患の治療剤 |
| JPWO2004026873A1 (ja) | 2002-09-18 | 2006-01-19 | 小野薬品工業株式会社 | トリアザスピロ［５．５］ウンデカン誘導体およびそれらを有効成分とする薬剤 |
| AU2003270783C1 (en) | 2002-09-20 | 2010-05-20 | Merck Sharp & Dohme Corp. | Octahydro-2-H-naphtho[1,2-F] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators |
| JP2004107299A (ja) | 2002-09-20 | 2004-04-08 | Japan Energy Corp | 新規１−置換ウラシル誘導体及びアレルギー性疾患の治療剤 |
| DE10246374A1 (de) | 2002-10-04 | 2004-04-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| MXPA05003866A (es) | 2002-10-11 | 2005-06-22 | Pfizer | Derivados de indol como agonistas beta-2. |
| EP1440966A1 (en) | 2003-01-10 | 2004-07-28 | Pfizer Limited | Indole derivatives useful for the treatment of diseases |
| AU2003298094A1 (en) | 2002-10-22 | 2004-05-13 | Glaxo Group Limited | Medicinal arylethanolamine compounds |
| KR20050065624A (ko) | 2002-10-23 | 2005-06-29 | 그렌마크 파머수티칼스 엘티디. | 염증성 및 알레르기 질환의 치료에 유용한 신규한트리사이클릭 화합물, 이의 제조 방법 및 이를 함유하는약제 조성물 |
| GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
| DE60320007T2 (de) | 2002-10-28 | 2009-06-18 | Glaxo Group Ltd., Greenford | Phenthanolamin-Derivate zur Behandlung von Atemwegserkrankungen |
| GB0225287D0 (en) | 2002-10-30 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| DE10253220A1 (de) | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| DE10253426B4 (de) | 2002-11-15 | 2005-09-22 | Elbion Ag | Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung |
| DE10253282A1 (de) | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung |
| DE10261874A1 (de) | 2002-12-20 | 2004-07-08 | Schering Ag | Nichtsteroidale Entzündungshemmer |
| US7019019B2 (en) * | 2002-12-23 | 2006-03-28 | Dendreon Corporation | Matriptase inhibitors and methods of use |
| AU2004207482B2 (en) | 2003-01-21 | 2009-10-08 | Merck Sharp & Dohme Corp. | 17-carbamoyloxy cortisol derivatives as selective glucocorticoid receptor modulators |
| PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| EP1460064A1 (en) | 2003-03-14 | 2004-09-22 | Pfizer Limited | Indole-2-carboxamide derivatives useful as beta-2 agonists |
| GB0507577D0 (en) * | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
-
2007
- 2007-11-21 AU AU2007342223A patent/AU2007342223B2/en not_active Ceased
- 2007-11-21 US US11/943,845 patent/US20080176901A1/en not_active Abandoned
- 2007-11-21 KR KR1020097014455A patent/KR101084787B1/ko not_active Expired - Fee Related
- 2007-11-21 RS RS20110129A patent/RS51644B/sr unknown
- 2007-11-21 EA EA200900920A patent/EA016199B1/ru not_active IP Right Cessation
- 2007-11-21 BR BRPI0720799-9A patent/BRPI0720799A2/pt not_active IP Right Cessation
- 2007-11-21 NZ NZ577939A patent/NZ577939A/en not_active IP Right Cessation
- 2007-11-21 DE DE602007011670T patent/DE602007011670D1/de active Active
- 2007-11-21 EP EP10013675A patent/EP2279777A2/en not_active Withdrawn
- 2007-11-21 AT AT07854747T patent/ATE493174T1/de active
- 2007-11-21 PL PL07854747T patent/PL2104535T3/pl unknown
- 2007-11-21 DK DK07854747.8T patent/DK2104535T3/da active
- 2007-11-21 PT PT07854747T patent/PT2104535E/pt unknown
- 2007-11-21 EP EP07854747A patent/EP2104535B9/en active Active
- 2007-11-21 HR HR20110201T patent/HRP20110201T1/hr unknown
- 2007-11-21 WO PCT/US2007/085366 patent/WO2008085608A1/en not_active Ceased
- 2007-11-21 MX MX2009007476A patent/MX2009007476A/es active IP Right Grant
- 2007-11-21 CA CA002673803A patent/CA2673803A1/en not_active Abandoned
- 2007-11-21 JP JP2009545545A patent/JP2010515729A/ja not_active Ceased
-
2008
- 2008-01-10 CL CL200800060A patent/CL2008000060A1/es unknown
- 2008-01-10 PE PE2008000105A patent/PE20081566A1/es not_active Application Discontinuation
- 2008-01-10 TW TW097101044A patent/TW200845981A/zh unknown
- 2008-01-10 AR ARP080100104A patent/AR064841A1/es not_active Application Discontinuation
-
2009
- 2009-06-30 MA MA32060A patent/MA31037B1/fr unknown
- 2009-07-08 TN TNP2009000294A patent/TN2009000294A1/fr unknown
- 2009-07-08 HN HN2009001282A patent/HN2009001282A/es unknown
- 2009-07-08 GT GT200900196A patent/GT200900196A/es unknown
- 2009-07-10 CU CU20090122A patent/CU23762B7/es not_active IP Right Cessation
- 2009-07-10 SV SV2009003330A patent/SV2009003330A/es not_active Application Discontinuation
- 2009-07-13 CO CO09072488A patent/CO6190626A2/es not_active Application Discontinuation
- 2009-07-15 EC EC2009009517A patent/ECSP099517A/es unknown
- 2009-08-10 NO NO20092817A patent/NO20092817L/no not_active Application Discontinuation
-
2011
- 2011-03-14 CY CY20111100283T patent/CY1111340T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230146291A1 (en) | Treatment of Respiratory Diseases | |
| McElvaney et al. | Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. | |
| Illum | Nasal delivery. The use of animal models to predict performance in man | |
| US20200297822A1 (en) | Methods, Compounds, and Compositions For Treatment and Prophylaxis in the Respiratory Tract | |
| JP6869979B2 (ja) | 新規なトリプシンアイソフォームおよびそれらの使用 | |
| US6849605B1 (en) | Inhibitors of serine protease activity, methods and compositions for treatment of viral infections | |
| KR20220079860A (ko) | 신규 펩티드 | |
| CN115427576B (zh) | 包括透明质酸和蛋白聚糖连接蛋白1的用于预防或治疗肺部疾病的组合物 | |
| Chughtai et al. | Potential role of inhibitors of neutrophil elastase in treating diseases of the airway | |
| Chen et al. | Overexpression of matrix metalloproteinases in lung tissue of patients with primary spontaneous pneumothorax | |
| CN103889436A (zh) | 用于延迟肺部症状加重的发作或进展的α1-蛋白酶抑制剂 | |
| Sommerhoff et al. | Inhibition of human neutrophil elastase by ICI 200,355 | |
| JP2003523393A (ja) | 呼吸器疾患治療用メタロプロティナーゼ阻害剤 | |
| US20070212343A1 (en) | Compositions for treatment of ear infections | |
| Shimizu et al. | Suppression of matrix metalloproteinase production in nasal fibroblasts by tranilast, an antiallergic agent, in vitro | |
| US20230044025A1 (en) | System and method of treating or preventing respiratory failure with aerosolized collagenase | |
| MYOU et al. | Type 1 angiotensin II receptor antagonism reduces antigen-induced airway reactions | |
| JP7759886B2 (ja) | 肺感染症の処置のための金含有薬剤 | |
| WO2020032910A1 (ru) | Фармацевтическая композиция, лекарственное средство и способ лечения бронхолегочных обструктивных заболеваний | |
| Willis et al. | Sino-orbital aspergillosis in a dog | |
| EP0804930A1 (en) | Novel remedy for respiratory-tract viral disease | |
| US6939851B1 (en) | Serine proteinase inhibitors | |
| US20240115567A1 (en) | Small therapeutic molecules capable of inhibiting the catalytic activity of the main protease enzyme of sars-cov-2 | |
| Kaliner | Recurrent sinusitis: examining medical treatment options | |
| CN102369012B (zh) | 氧化氘用于治疗病毒性呼吸道疾病的用途 |